anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A hair preparation comprises an oestrogenic hormone or hormones in admixture with one or more of the amino acids cystine, methionine, lysine, tyrosine, phenylalanine and glycine.  The amino acids comprise 0.1 to 10 per cent. of the preparation.  The preferred preparation is aqueous, contains sodium chloride or sodium bicarbonate and is buffered at pH8 to 8.5.  The preparation may be in the form of solution, suspension or emulsion, which may be perfumed and coloured and contain a preservative.  Optional ingredients specified are (a) cosmetic diluents such as diethylene glycol monoethyl ether, polyethylene glycol (300), benzyl alcohol, propylene glycol, terpineol, industrial methylated spirits, vegetable oils, isopropyl myristate and (b) the emulsifying and dispersing agents mixed palm kernel esters of polyethylene glycol 400, triethanolamine lauryl sulphate and emulsifying wax.  The hormone may be natural or synthetic e.g. oestradiol benzoate.
PURPOSE:To obtain an aldose reductase inhibitor comprising an extracted component of Garcinia spicate as an active ingredient. CONSTITUTION:This aldose reductase inhibitor comprises an extracted component obtained from Garcinia spicate with a solvent as an active ingredient. Garcinia spicate is dried and extracted with a solvent. Then the organic solvent containing the extracted component is concentrated and the extracted component is isolated. A part to be extracted is not particularly limited and leaves, stems, roots, etc., are preferable. Hexane, ethyl acetate, dichloromethane, chloroform, acetone, water and a solution of an alcohol such as methanol, ethanol or n- butanol can be applied as the organic solvent used for reflux and extraction.
An improved sunscreen protection and insect repellent combination compound having an SPF factor of 15 and further having an unexpected unusually long efficacy period when used in rainy conditions and prolonged periods of high humidity as in tropical and sub-tropical rain forests or the like, and in underwater conditions as in swimming. The compound forms a lotion that is easy to store. The lotion can be applied to the skin of a person with little or no training. No special precautions are required by the person when applying the lotion. The compound has a sweet taste when applied to the lips and is pleasantly scented. The compound forms a thin film on the skin, but is non-greasy to the touch. The lotion is easily removed by scrubbing with soap and water. The sunscreen component being about between 4% to 8% by weight, the insect repellent compound being about between 12% to 22% by weight, and the water based solvent being about between 27% to 37% by weight.
FIELD: organic chemistry. SUBSTANCE: invention relates to a novel salt, namely, (R)-3-N, N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyrane- 5-carboxamide acid tartrate, in part, its (2R,3R)-tartrate and especially to (R)-3-N, N, -dicyclobutylamino- 8-fluoro-3,4-dihydro-2H-1-benzopyrane-5-carboxamide acid (2R,3R)-tartrate monohydrate. Invention relates also to method of synthesis of indicated tartrate salt and pharmaceutical composition based on thereof used for treatment and prophylaxis of central nervous system (CNS) disorders and corresponding impairments of medicinal nature associated with activity of antagonist of 5-HT 1A -receptors. Invention provides the preparing the novel salt of (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1- benzopyrane-5-carboxamide showing good solubility with low degree of hygroscopicity that makes the preparation based on thereof to be more stable in prolonged storage and the most useful in terms of quality guarantee. EFFECT: improved method of synthesis and preparing, valuable medicinal properties of salt. 14 cl, 2 dwg _
Experimental Group 1 (GE1): Created for pregnant women who carry out their own program of each monitor in the different sports centers and public and private swimming pools in the South of the Autonomous Community of Galicia. These own programs will all have the same format: initial warm-up phase, main part of indicated and personalized exercises for pregnancies and final phase with a return to calm.
Radioiodine therapy in thyroid carcinoma is a procedure performed for over six decades, and there is a vast literature in respect of its value in the complementary treatment of this neoplasia. This procedure also promotes a reliable follow-up based on sequential thyroglobulin dosages and makes possible to reduce the disease recurrence rate. One of the main aspects of the patients preparation before receiving the radioiodine consists in promoting stimulation for an effective uptake of the radioiodine, obtained either by endogenously TSH level elevation after post-surgical thyroid hormone withdrawal, or exogenously after use of recombinant human TSH. This last alternative does not demand suspension of thyroid hormone reposition after total thyroidectomy. Although not fully comprehended, it is known that hypothyroidism results in renal function hazard, which is reverted after hormonal reposition. It is also known that renal function modifies the radioiodine residence time and that the longer this time, the greater the patient's radiation exposure will be, and consequently with undesired irradiation of healthy tissues and organs. So theoretically stimulating the patient with recombinant human TSH could avoid the transient deficient renal function, promoting a lower radioiodine residence time and consequently lowering radiation exposure in this therapy.

This project aims to evaluate the effects of the different stimulation, endogenous and exogenous, over renal function by glomerular filtration rate determined by 51Cr-EDTA. This will be a controlled and randomized study in which 44 patients that has clinical indication of remnant ablative radioiodine treatment will be prepared by either one of the TSH stimulation procedures. Additionally radiation dosimetry calculus will be done to analyze the levels of the patient's radiation exposure associated with each of the uptake stimulation procedures for radioiodine therapy.
The invention relates to a natural biological crosslinking nanocomposite three-dimensional gel bracket and a preparation method. Hydrogel contains an acrylamide monomer M1, inorganic nanometer clay M2, biomacromolecule M3 and genipin M4 as a biological crosslinking agent, wherein the mass percent of the dosage of the acrylamide monomer M1 to the inorganic nanometer clay M2 to the biomacromolecule M3 to the genipin M4 is (55-90):(7-25):(3-20):(0-5). The preparation method disclosed by the invention comprises the following steps that in a water solution, the M2 is used as a crosslinking agent of the M1, the M4 is used as a crosslinking agent of the M3, and a method of free radical polymerization in situ and a phase separation and freeze-drying method are adopted to prepare the nanocomposite three-dimensional gel bracket with excellent biocompatibility and mechanical property. The method has the advantages of easiness and convenience in operation, controllability, no need of large equipment, no poison and no harm of water phase reaction, and no pollution of the environment. The mechanical strength of the bracket is increased by introducing the biological crosslinking agent, cells can grow and proliferate inside and outside the bracket, and good microenvironment is provided for tissue regeneration. The nanocomposite three-dimensional gel bracket disclosed by the invention can be used for medical transplanting, drug release and cell culture.
<P>PROBLEM TO BE SOLVED: To provide an image display method and device and a medical image display program which can smoothly read images when the medical images are arranged and displayed.  <P>SOLUTION: A discriminating part 44 mutually compares the contents of the attendant information of the four medical images 17 displayed on an image display screen 46 respectively for items and discriminates the attendant information common to all the medical images 17 as common information 53. Other attendant information than the common information 53 is specific information 54. When taking an area for displaying the attendant information as the common information 53 to be located in the side of each of non-imaging areas 52 of the four medical images 17 where other medical image 17 is not adjacently displayed and the four medical images 17 as one medical image 17, the area setting part 45 allocates the area to an area corresponding to a prescribed area when the one medical image 17 is displayed on the image setting screen 46. The area setting part 45 allocates an area for displaying the attendant information as the specific information 54 to an area located in the side of each of the non-imaging areas 52 of the four medical images 17 where other medical images 17 is adjacently displayed and symmetrical with respect to boundary lines 55 to 58 of the adjacent medical images 17.  <P>COPYRIGHT: (C)2010,JPO&INPIT
PURPOSE:To obtain the titled compound which is a synthetic intermediate for an antibiotic substance prumycin useful as an antitumor agent, etc., in high yield and selectivity, by using (D)-arabinose as a starting raw material and carrying out the synthesis using a specific process. CONSTITUTION:The objective compound of formula VIII can be produced by (1) converting (D)-arabinose of formula I to benzylglycoside derivative with a compound of formula BnOH (Bn is benzyl which may be substituted with halogen, etc.), (2) reacting the obtained compound of formula III with a compound of formula (R2)2O (R2 is acetyl, benzoyl, etc.) and hydrolyzing the reaction product, (3) sulfonating the resultant compound of formula IV with a compound of formula R3Cl (R3 is methylsulfonyl, etc.), (4) azidizing the product to obtain the compound of formula V, (5) epoxidizing the compound with an alkali and ammonolyzing the product and (6) reacting the resultant compound of formula VI with a compound of formula CbzHal [Cbz is group of formula VII (X is lower alkyl, etc.)].
Patients will receive CNT-01 500 mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
The duration of the study will be 60 days (8 weeks). Each day they will have to consume the product under investigation. Subjects who meet the selection criteria will be randomized into each of the study groups (A, B, C o D, depending on the group in which they have been randomized). Each day the subjects will have to fill in a diary regarding pain and concomitant medication.

They will make a total of two visits to the research laboratory and will perform the tests pre-established in the protocol. In addition, a follow-up telephone call will be made after 30 days of consume. Subsequently, a statistical analysis will be performed with the variables measured in the study to obtain the results.
Patients receive navitoclax PO QD and vistusertib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
This document teaches a computer-implemented system for simulating a mental state of a mind of a human. The system comprises a memory including a plurality of instructions, virtual data storage and human mental data storage. The mental data storage stores mental data relating to the mental state of the mind of the human. At least one processor can execute ones of the plurality of instructions to generate at least a digital twin of the mind of the human. The digital twin includes one or more models of the mind of the human based on human mental data. The one or more models of the mind are stored in a virtual data storage and enable analysis of the mind of the human by the at least one processor within the virtual data storage. The digital twin includes a link between the mental data storage and the virtual data storage.
This is a Phase Ib open-label, 2-Part, multi-center study in China. The study will be conducted in two stages: Stage 1 is the dose-escalation part, which is designed to evaluate the safety, tolerability, PK and efficacy, as well as to determine the maximum tolerable dosage (MTD) or maximum applicable dose (MAD) of HS-10352 in combination with fulvestrant. Stage 2 is the dose-expansion part, which is aimed to further assess the efficacy, safety, tolerability and PK, and to establish the recommended phase 2 dose (RP2D) of HS-10352 in combination with fulvestrant.

All participants will be carefully monitored for adverse events (AE) during the study treatment and for 28 days after the last dose of study drug. The PK characteristics of HS-10352 and fulvestrant will be evaluated from C1 to C6. Subjects of this study will be assessed for progression once every 8 weeks until objective disease progression or withdrawal from the trial. As the disease progresses, survival follow-up is recommended bimonthly.
The invention relates to an animal agent with heat clearing and detoxicating, while it can diminish the inflammation and reduce the pain. Wherein, it uses isatic root as material; and the production comprises that cleaning the isatic root cutting and broking; extracting it in the water at 8 mass times than drug, while the extracting temperature is 95+-3Deg. C; in the first time, extracting with 10% acid to adjust the pH value to 2-5, to be boiled for 2 hours; in the second time, adding water that 8 times of drug, using 10% alkali to adjust the pH value to 8-9, and extracting for 1.5hours; filtering and combining the solution, then drying and broking into isatic root powder. The invention can effectively treat animal disease. The invention uses water extraction and adds acid before adding alkali to keep the effective component of drug. And it can improve the breeding benefit and reduce the production cost of drug.
E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV strain Brescia during infection in the natural host. The three putative glycosylation sites in E1 were modified by site directed mutagenesis of a CSFV Brescia infectious clone (BICv). A panel of virus mutants was obtained and used to investigate whether the removal of putative glycosylation sites in the E1 glycoprotein would affect viral virulence/pathogenesis in swine. We observed that rescue of viable virus was completely impaired by removal of all three putative glycosylation sites in E1. Single mutations of each of the E1 glycosylation sites showed that CSFV amino acid N594 (E1.N3 virus), as well the combined mutation of N500 and N513 (E1.N1N2 virus) resulted in BICv attenuation. Infection of either E1.N1N2 or E1.N3 viruses were able to efficiently protected swine from challenge with virulent BICv at 3 and 28 days post-infection. These results, along with those demonstrating the role of glycosylation of E rns  and E2, suggest that manipulation of the pattern of glycosylation could be a useful tool for development of CSF live-attenuated vaccines.
GV-TH-01 is an open label Phase 1 study of 9 HIV-1 infected adults with suppressed viremia who started anti-retroviral therapy (ART) within 18 months of a negative HIV antibody test. This study has 3 phases. The first phase is the vaccination phase, where patients are vaccinated with pGA2/JS7 (JS7)DNA and MVA62B vaccines on a prime/boost regimen at weeks 1 and 9 (JS7 DNA vaccine) and weeks 17 and 25 (MVA62B). Both vaccines express Gag, Pol, and Env. The second phase of the study is a treatment interruption phase, whereby ART is interrupted for a 12 week period approximately 8 weeks following the last vaccination. The third phase occurs after the 12 week treatment interruption phase and is called the treatment reinstitution phase, because subjects reinstitute ART and are followed for an additional 24 weeks. The primary objective is to evaluate the safety of the vaccines during the three phases of the study. A secondary objective is to evaluate the immunogenicity of the vaccines during the vaccination phase of the study.
PURPOSE:To provide an antiallergic agent containing a nicotinoylbenzoguanamine derivative or its acid addition salt as a main component. CONSTITUTION:The objective antiallergic agent is prepared by adding 0.1- 99.5%, preferably 0.5-90% of the compound of formula [X and Y are H or halogen provided that X and Y are not H at the same time; Z is mono(lower alkyl)amino, di(lower alkyl)amino, piperidino, pyrrolidino or morpholino] or its acid addition salt to a non-toxic inert carrier. Dose: 4-40mg/kg, preferably 6-12mg/kg of the active component daily in 1-4 divided doses by oral, parenteral, local or transrectal administration, especially preferably in the form of tablet or capsule. The compound of formula has strong activity to suppress passive Arthus reaction, and is effective for the remedy of II-type allergy (e.g. myasthenia gravis), III-type allergy (e.g. systemic lupus erythemotosus), etc.
Interactive PTB with Bluetooth® 4.0 connectivity smartphone app with Cross Action brush head using visually position detection feature. A triple pressure control system stops vibration, gives a visual warning, and reduces rotation speed in Daily Cleaning Mode-1.
CONCERTA® is a central nervous system (CNS) stimulant. CONCERTA® is available in four tablet strengths. Each extended-release tablet for once-a-day oral administration contains 18, 27, 36, or 54 mg of methylphenidate HCl USP and is designed to have a 12-hour duration of effect. Chemically, methylphenidate HCl is d,l (racemic) methyl α-phenyl-2-piperidineacetate hydrochloride. Its empirical formula is C14H19NO2•HCl. Its structural formula is:

Methylphenidate HCl USP is a white, odorless crystalline powder. Its solutions are acid to litmus. It is freely soluble in water and in methanol, soluble in alcohol, and slightly soluble in chloroform and in acetone. Its molecular weight is 269.77.

CONCERTA® also contains the following inert ingredients: butylated hydroxytoluene, carnauba wax, cellulose acetate, hypromellose, lactose, phosphoric acid, poloxamer, polyethylene glycol, polyethylene oxides, povidone, propylene glycol, sodium chloride, stearic acid, succinic acid, synthetic iron oxides, titanium dioxide, and triacetin.
Participants utilize a FitBit to monitor their physical activity and receive electronic newsletters twice monthly during months 1-3 and monthly during months 4-6 to share basic health education related to physical activity and provide support for engagement. Participants also wear an accelerometer for a minimum of 10 hours a day for 7 days.
The goal of computational psychiatry is to gain knowledge about underlying neurocomputational processes that underpin psychiatric disorders and to leverage this knowledge for improving diagnosis and treatment. A key step toward achieving this goal is to develop measures of individual differences in computations obtained from a single individual that are reliable, robust and meaningfully relevant to psychiatric dysfunction. In order to attain these objectives, it is essential we substantiate relationships between candidate computational mechanisms and diagnostic categories, symptom dimensions and treatment outcomes. In the present study, a computational assessment task battery (CAB) will be utilized that is designed to measure individual differences across a multidimensional array of computational processes. The study aims to separate three different variance components contributing to variability in computational parameter estimation: occasion-related variance due to incidental day to day changes in task performance, state-dependent variance that is related to meaningful variation across time in the underlying computations within an individual, and trait-related differences pertaining to stable individual differences in computations across individuals. To accomplish this, repeated assessments will be implemented using this battery across a 1-year interval within an on-line sample, and use hierarchical Bayesian modeling to separate the effect of occasion, state and trait-related variance on these parameter estimates. These variance components will then be related to diagnostic categories, symptom dimensions and symptom severity measures in a diverse cohort of psychiatric patients (mostly with depression, anxiety and OCD) recruited in Southern California. Finally, the relationship will be tracked between the computational parameter estimates and changes in symptoms across time in a subset of these patients. This study promises to significantly advance understanding of how to reliably extract diagnostically relevant computationally-derived measures of cognitive phenotypes that could eventually be migrated to the clinic.
The disclosure describes, in various example embodiments, a small arms or firearm projectile including a shell and a hemostatic material retained within the shell. The hemostatic material has a mechanical modulus above 25,000 Pa. In some embodiments, the shell includes a plurality of perforations. In some embodiments, the plurality of perforations are configured to provide, upon an impact of the projectile, fluid communication between the hemostatic material and the exterior of the shell via the plurality of perforations. In some embodiments, the hemostatic material includes a polymer core configured to provide a scaffold for inducing hemostasis in a local wound volume. In some embodiments, the projectile includes a contrasting agent. In some embodiments, the projectile includes a lubricating agent retained in the interior of the shell. In some embodiments, the projectile further includes 0.5 to 3 grains of Kaolin retained in the interior of the shell.